SOLICITATION NOTICE
65 -- Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program - Newly Approved Drug Appendices - RFQ Newly Approved Drugs
- Notice Date
- 9/9/2019
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- Other Defense Agencies, Defense Health Agency, Contracting Office - Aurora, 16401 E. Centretech Pkwy, Aurora, Colorado, 80011, United States
- ZIP Code
- 80011
- Solicitation Number
- HT9402-19-Q-0006(2)
- Point of Contact
- Alexia Ray, Phone: 210-536-6020, Yvette H. Dluhos, Phone: 210-536-6048
- E-Mail Address
-
alexia.m.ray.ctr@mail.mil, yvette.h.dluhos.civ@mail.mil
(alexia.m.ray.ctr@mail.mil, yvette.h.dluhos.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- Solicitation for Newly Approved Drugs NAD Appendix2 - Xenleta- Antiinfectives - Miscellaneous NAD Appendix2 - Vyleesi - Gynecological Agents Miscellaneous - NA NAD Appendix2 - Turalio - Oncological Agents - NA NAD Appendix2 - Rozlytrek- Oncological Agents - Lung Cancer NAD Appendix2 - Rinvoq ER- TIBS - Miscellaneous NAD Appendix2 - Inrebic - Oncological Agents - NA Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: November 2019: The following drug classes/subclass and newly approved agents will be reviewed: Oncological Agents, SUB CLASS: NA - Inrebic TIBS, SUB CLASS: Miscellaneous - Rinvoq ER Oncological Agents, SUB CLASS: Lung Cancer - Rozlytrek Oncological Agents, SUB CLASS: NA- Turalio Gynecological Agents Miscellaneous, SUB CLASS: NA - Vyleesi Antiinfectives, SUB CLASS: Miscellaneous - Xenleta RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein. There is no pre-proposal teleconference. Rather, questions shall be submitted via e-mail to the Request for Quote (RFQ) Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required. POCs: Part 2.3 of the RFQ. For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/d6951e6c6f4d92de223cd2b57db39291)
- Place of Performance
- Address: 7800 IH-10 West, Ste 400, San Antonio, Texas, 78230, United States
- Zip Code: 78230
- Zip Code: 78230
- Record
- SN05436296-W 20190911/190909230851-d6951e6c6f4d92de223cd2b57db39291 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |